103 related articles for article (PubMed ID: 32809875)
1. Proteomic Signatures During Treatment in Different Stages of Heart Failure.
Michelhaugh SA; Camacho A; Ibrahim NE; Gaggin H; D'Alessandro D; Coglianese E; Lewis GD; Januzzi JL
Circ Heart Fail; 2020 Aug; 13(8):e006794. PubMed ID: 32809875
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.
Vasquez N; Carter S; Grodin JL
Curr Heart Fail Rep; 2020 Jun; 17(3):67-76. PubMed ID: 32394149
[TBL] [Abstract][Full Text] [Related]
3. Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40.
Zhao M; Xin Y; Li J; Cao X; Liu X
Medicine (Baltimore); 2019 Sep; 98(39):e17296. PubMed ID: 31574852
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
[TBL] [Abstract][Full Text] [Related]
6. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
7. Characterization of heart failure patients with reverse left ventricular remodelling post-angiotensin receptor blockers/neprilysin inhibitors therapy.
Maizels L; Wasserstrum Y; Fishman B; Segev A; Ben-Nun D; Younis A; Freimark D; Mazin I; Grupper A
ESC Heart Fail; 2022 Jun; 9(3):1682-1688. PubMed ID: 35178886
[TBL] [Abstract][Full Text] [Related]
8. Diuretic and renal effects of angiotensin receptor-neprilysin inhibitor in patients hospitalized for acute heart failure.
Setoguchi N; Horiuchi Y; Kawakami T; Nakase M; Watanabe Y; Ishizawa T; Sekiguchi M; Nakajima M; Nonaka H; Asami M; Yahagi K; Komiyama K; Yuzawa H; Tanaka J; Aoki J; Tanabe K
Heart Vessels; 2023 Aug; 38(8):1042-1048. PubMed ID: 36854753
[TBL] [Abstract][Full Text] [Related]
9. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
[TBL] [Abstract][Full Text] [Related]
10. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
Kimmoun A; Cotter G; Davison B; Takagi K; Addad F; Celutkiene J; Chioncel O; Solal AC; Diaz R; Damasceno A; Duengen HD; Filippatos G; Goncalvesova E; Merai I; Metra M; Ponikowski P; Privalov D; Sliwa K; Sani MU; Voors AA; Shogenov Z; Mebazaa A
Eur J Heart Fail; 2019 Nov; 21(11):1459-1467. PubMed ID: 31423712
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction.
Docherty KF; McMurray JJV
Int J Cardiol; 2019 Apr; 281():179-185. PubMed ID: 29891240
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin receptor neprilysin inhibitor use in patients with left ventricular assist devices: A single-center experience.
Alishetti S; Braghieri L; Jennings DL; Uriel N; Colombo PC; Yuzefpolskaya M
Int J Artif Organs; 2022 Jan; 45(1):118-120. PubMed ID: 33467950
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction.
Park SY; Kong MG; Moon I; Park HW; Choi HO; Seo HS; Cho YH; Lee NH; Lee KY; Jang HJ; Kim JS; Choi IJ; Suh J
Korean J Intern Med; 2023 Sep; 38(5):692-703. PubMed ID: 37648226
[TBL] [Abstract][Full Text] [Related]
14. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis.
O'Meara E; McDonald M; Chan M; Ducharme A; Ezekowitz JA; Giannetti N; Grzeslo A; Heckman GA; Howlett JG; Koshman SL; Lepage S; Mielniczuk LM; Moe GW; Swiggum E; Toma M; Virani SA; Zieroth S; De S; Matteau S; Parent MC; Asgar AW; Cohen G; Fine N; Davis M; Verma S; Cherney D; Abrams H; Al-Hesayen A; Cohen-Solal A; D'Astous M; Delgado DH; Desplantie O; Estrella-Holder E; Green L; Haddad H; Harkness K; Hernandez AF; Kouz S; LeBlanc MH; Lee D; Masoudi FA; McKelvie RS; Rajda M; Ross HJ; Sussex B
Can J Cardiol; 2020 Feb; 36(2):159-169. PubMed ID: 32036861
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin Receptor-Neprilysin Inhibition Improves Blood Pressure and Heart Failure Control in Left Ventricular Assist Device Patients.
Goldberg RL; Freed KE; Klemans N; Fioretti R; Choi CW; Kilic A; Adamo L; Florido R; Sharma K; Gilotra NA; Hsu S
ASAIO J; 2021 Dec; 67(12):e207-e210. PubMed ID: 33883502
[TBL] [Abstract][Full Text] [Related]
16. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
[TBL] [Abstract][Full Text] [Related]
17. Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.
Prenner SB; Shah SJ; Yancy CW
Curr Atheroscler Rep; 2016 Aug; 18(8):48. PubMed ID: 27324636
[TBL] [Abstract][Full Text] [Related]
18. Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure.
Luo N; Ballew NG; O'Brien EC; Greiner MA; Peterson PN; Hammill BG; Hardy NC; Laskey WK; Heidenreich PA; Chang CL; Hernandez AF; Curtis LH; Mentz RJ; Fonarow GC
Am Heart J; 2018 Jun; 200():134-140. PubMed ID: 29898842
[TBL] [Abstract][Full Text] [Related]
19. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.
Peri-Okonny PA; Mi X; Khariton Y; Patel KK; Thomas L; Fonarow GC; Sharma PP; Duffy CI; Albert NM; Butler J; Hernandez AF; McCague K; Williams FB; DeVore AD; Patterson JH; Spertus JA
JACC Heart Fail; 2019 Apr; 7(4):350-358. PubMed ID: 30738978
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
